AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Gilead Sciences Stock Drops 1% as CVS Rejects HIV Prevention Drug
ByAinvest
Saturday, Aug 23, 2025 4:53 am ET1min read
Gilead Sciences' stock dropped 1% after CVS Health decided not to cover its new HIV prevention drug, Yeztugo, citing clinical, financial, and regulatory factors. Gilead had previously hailed the FDA approval of Yeztugo, which is aimed at reducing the risk of acquiring HIV through sex. Analysts note that CVS coverage delays are not concerning for Yeztugo's broad coverage goals and upcoming coverage decisions from UnitedHealth and Cigna could be more significant catalysts.
Gilead Sciences' (NASDAQ: GILD) stock dropped by 1% following CVS Health's (NYSE: CVS) announcement that it will not cover the company's new HIV prevention drug, Yeztugo. The decision was made based on clinical, financial, and regulatory considerations, according to a CVS spokesperson [1]. Yeztugo, an injectable HIV-1 capsid inhibitor, was approved by the FDA in June 2025 for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35 kg [2].The twice-yearly injection, priced at over $28,000 annually, will not be included in CVS's commercial plans or Affordable Care Act (ACA) formularies. CVS's ACA preventive program follows recommendations and mandates from the U.S. Department of Health and Human Services (HHS). Current HIV prevention recommendations from the U.S. Preventive Services Task Force, supported by HHS, only include three older medications [1].
While Gilead is still in negotiations with CVS regarding Yeztugo coverage, the company is making progress with other health insurance companies and payers. Reuters reports that Gilead is on track to secure 75% of U.S. insurer coverage of Yeztugo by year-end and 90% coverage by June 2026 [3].
Analysts note that CVS's decision to delay coverage is not a significant concern for Yeztugo's broad coverage goals. Upcoming coverage decisions from UnitedHealth and Cigna could have a more substantial impact on the drug's market penetration and Gilead's financial performance.
References:
[1] https://www.investing.com/news/stock-market-news/cvs-health-wont-cover-gileads-new-hiv-prevention-drug-yeztugo--reuters-93CH-4203165
[2] https://www.idse.net/FDA-News/Article/06-25/Yeztugo-FDA-Approved-HIV-PrEP/77487
[3] https://www.washingtonblade.com/2025/08/22/cvs-health-withholds-coverave-new-hiv-prevention-drug/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet